Use of low-molecular-weight heparin from the first trimester of pregnancy: A retrospective study of 111 consecutive pregnancies

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 127, Issue 1, 2006, Pages 73-78

  Deruelle, Philippe ^a   Denervaud, Muriel ^a   Hachulla, Eric ^a   Ducloy Bouthors, Anne Sophie ^a   Valat, Anne Sylvie ^a   Puech, Francis ^a   Trillot, Nathalie ^a   Hatron, Pierre Yves ^a   Subtil, Damien ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Low molecular weight heparin; Pregnancy; Teratogenicity; Thrombophilia; Thrombosis

Indexed keywords

DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CLEFT LIP; CLEFT PALATE; CONGENITAL MALFORMATION; CONTROLLED STUDY; CURETTAGE; DRUG TOLERABILITY; DRUG USE; ECCHYMOSIS; EPISTAXIS; FEMALE; FETUS WASTAGE; FIRST TRIMESTER PREGNANCY; GINGIVORRHAGIA; HEMATOMA; HEMATURIA; HIGH RISK PREGNANCY; HUMAN; INJECTION SITE BLEEDING; INJECTION SITE PAIN; INJECTION SITE REACTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; NEONATAL HEMORRHAGE; NEWBORN; POSTPARTUM HEMORRHAGE; PRIORITY JOURNAL; PYELECTASIA; RECURRENT DISEASE; SECOND TRIMESTER ABORTION; SKIN CYST; SKIN MANIFESTATION; SOLUTIO PLACENTAE; SPONTANEOUS ABORTION; STROKE; THERAPEUTIC ABORTION; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT INDICATION; UTERINE ARTERY EMBOLIZATION;

EID: 33745384234     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2005.09.010     Document Type: Article

References (27)

1. Barbour L.A. Current concepts of anticoagulant therapy in pregnancy. Obstet Gynecol Clin N Am 24 3 (1997) 499-521
2. Heilmann L., Schneider D.M., and von Tempelhoff G.F. Antithrombotic therapy in high-risk pregnancy. Hematol Oncol Clin N Am 14 5 (2000) 1133-1150
3. McColl M.D., Ramsay J.E., Tait R.C., et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 78 4 (1997) 1183-1188
4. Ginsberg J.S. Thromboembolism and pregnancy. Thromb Haemost 82 2 (1999) 620-625
5. Dimitrakakis C., Papageorgiou P., Papageorgiou I., Antzaklis A., Sakarelou N., and Michalas S. Absence of transplacental passage of the low molecular weight heparin enoxaparin. Haemostasis 30 5 (2000) 243-248
6. Brenner B., Hoffman R., Blumenfeld Z., Weiner Z., and Younis J.S. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost 83 5 (2000) 693-697
7. Bar J., Mashiah R., Cohen-Sacher B., et al. Effect of thrombophylaxis on uterine and fetal circulation in pregnant women with a history of pregnancy complications. Thromb Res 101 4 (2001) 235-241
8. Robin F., Lecuru F., Desfeux P., Boucaya V., and Taurelle R. Anticoagulant therapy in pregnancy. Eur J Obstet Gynecol Reprod Biol 83 2 (1999) 171-177
9. Omri A., Delaloye J.F., Andersen H., and Bachmann F. Low molecular weight heparin Novo (LHN-1) does not cross the placenta during the second trimester of pregnancy. Thromb Haemost 61 1 (1989) 55-56
10. Warkentin T.E., Levine M.N., Hirsh J., et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332 20 (1995) 1330-1335
11. Shefras J., and Farquharson R.G. Bone density studies in pregnant women receiving heparin. Eur J Obstet Gynecol Reprod Biol 65 2 (1996) 171-174
12. Pettila V., Kaaja R., Leinonen P., Ekblad U., Kataja M., and Ikkala E. Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thromb Res 96 4 (1999) 275-282
13. Sanson B.J., Lensing A.W., Prins M.H., et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 81 5 (1999) 668-672
14. Nelson-Piercy C., Letsky E.A., and de Swiet M. Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol 176 5 (1997) 1062-1068
15. Melissari E., Parker C.J., Wilson N.V., et al. Use of low molecular weight heparin in pregnancy. Thromb Haemost 68 6 (1992) 652-656
16. Blomback M., Bremme K., Hellgren M., Siegbahn A., and Lindberg H. Thromboprophylaxis with low molecular mass heparin, 'Fragmin' (dalteparin), during pregnancy-a longitudinal safety study. Blood Coagul Fibrinol 9 1 (1998) 1-9
17. Hunt B.J., Doughty H.A., Majumdar G., et al. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thromb Haemost 77 1 (1997) 39-43
18. Leroy B., and Lefort F. The weight and size of newborn infants at birth. Rev Fr Gynecol Obstet 66 6 (1971) 391-396
19. Lepercq J., Conard J., Borel-Derlon A., et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. Br J Obstet Gynecol 108 11 (2001) 1134-1140
20. Ananth C.V., and Savitz D.A. Vaginal bleeding and adverse reproductive outcomes: a meta-analysis. Paediatr Perinat Epidemiol 8 1 (1994) 62-78
21. Ginsberg J.S., Greer I., and Hirsh J. Use of antithrombotic agents during pregnancy. Chest 119 1 Suppl. (2001) 122S-131S
22. Anderson D.R., Ginsberg J.S., Burrows R., and Brill-Edwards P. Subcutaneous heparin therapy during pregnancy: a need for concern at the time of delivery. Thromb Haemost 65 3 (1991) 248-250
23. Brill-Edwards P., Ginsberg J.S., Gent M., et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of clot in this Pregnancy Study Group. N Engl J Med 343 20 (2000) 1439-1444
24. Ray J.G., and Chan W.S. Deep vein thrombosis during pregnancy and the puerperium: a meta-analysis of the period of risk and the leg of presentation. Obstet Gynecol Surv 54 4 (1999) 265-271
25. Brenner B., Mandel H., Lanir N., et al. Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol 97 3 (1997) 551-554
26. Patterson R.M., Gibbs C.E., and Wood R.C. Birth weight percentile and perinatal outcome: recurrence of intrauterine growth retardation. Obstet Gynecol 68 4 (1986) 464-468
27. Visser G.H., Huisman A., Saathof P.W., and Sinnige H.A. Early fetal growth retardation: obstetric background and recurrence rate. Obstet Gynecol 67 1 (1986) 40-43